Cuprina Appoints Dr. Ronald Sherman, Leader in Maggot Debridement Therapy, as Medical and ...

Cuprina Appoints Dr. Ronald Sherman, Leader in Maggot Debridement Therapy, as Medical and ...

SINGAPORE, July 21, 2025 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“CUPR” or “the Company”), a biomedical and biotechnology company dedicated to the development and commercialization of products for the management of chronic wounds and infertility, as well…

Cuprina names Dr. Ronald Sherman as medical and scientific director; secures FDA-approved medical maggot license - BioTuesdays

Cuprina Holdings (NASDAQ: CUPR) has announced the appointment of Dr. Ronald Sherman, a leading innovator in maggot debridement therapy (MDT), as medical and scientific director, effective September 2025—securing the license for Dr. Sherman’s FDA-cleared Lucilia sericata medical maggots. According to a June 2025 study by Research and Markets, the US market for maggot debridement therapy in 2024 was valued at $13.9 million, and was projected to gr…